Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

Sumitra Thongprasert,Sarayut Lucien Geater,Dana Clement,A. Abdelaziz,Jasmin Reyes-Igama,Dragana Jovanovic,A. Alexandru,Michael Schenker,Virote Sriuranpong,Piotr Serwatowski,Sheethal Suresh,A. Cseh,Rabab Gaafar

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

2019

Sumitra Thongprasert
Sarayut Lucien Geater
Dana Clement
A. Abdelaziz
Jasmin Reyes-Igama
Dragana Jovanovic
A. Alexandru
Michael Schenker
Virote Sriuranpong
Piotr Serwatowski
Sheethal Suresh
A. Cseh
Rabab Gaafar

Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy.

Keywords:

Afatinib
Cancer research
Chemotherapy
Medicine
Diarrhea
Clinical endpoint
Oncology
Tolerability
Rash
Internal medicine
Lung cancer
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations